Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | PDE4A | P27815 | 5/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.34 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10108972 | 0.79 | ACHE (0.47) | NPC1ACHEKDM4ELMNARAB9A | |
| SCHEMBL318028 | 0.79 | ACHE (0.47) | NPC1ACHEKDM4ELMNARAB9A | |
| SCHEMBL318776 | 0.79 | MEN1 (0.38) | NPC1KMT2AMEN1ACHEPDE4A | |
| SCHEMBL10109421 | 0.79 | MEN1 (0.38) | NPC1KMT2AMEN1ACHEPDE4A | |
| SCHEMBL10109131 | 0.72 | ACHE (0.43) | NPC1KMT2AMEN1ACHEALDH1A1 | |
| SCHEMBL317987 | 0.72 | ACHE (0.43) | NPC1KMT2AMEN1ACHEALDH1A1 | |
| SCHEMBL7311616 | 0.69 | HPGD (0.57) | NPC1KMT2AMEN1ACHEALDH1A1 | |
| SCHEMBL318058 | 0.68 | LMNA (0.47) | NPC1KMT2AACHEMAP2K3ALDH1A1 | |
| SCHEMBL10108810 | 0.68 | LMNA (0.47) | NPC1KMT2AACHEMAP2K3ALDH1A1 | |
| SCHEMBL10108843 | 0.65 | LMNA (0.47) | ACHEMAP2K3ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093302-B2 | Substituted tetralins as selective estrogen receptor-β agonists | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ELI LILLY AND COMPANY (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249075-A1 | SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS | ESR2, ERLIN1, ESRRG | NPC1 2576/4885KMT2A 2706/4885MEN1 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.